Compare AJANTA PHARMA with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SUN PHARMA AJANTA PHARMA/
SUN PHARMA
 
P/E (TTM) x 24.4 79.8 30.6% View Chart
P/BV x 6.8 3.4 199.2% View Chart
Dividend Yield % 0.5 0.6 83.2%  

Financials

 AJANTA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
SUN PHARMA
Mar-20
AJANTA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,422484 293.7%   
Low Rs898315 284.8%   
Sales per share (Unadj.) Rs233.5136.9 170.6%  
Earnings per share (Unadj.) Rs44.017.5 251.9%  
Cash flow per share (Unadj.) Rs52.226.0 200.5%  
Dividends per share (Unadj.) Rs9.004.00 225.0%  
Dividend yield (eoy) %0.81.0 77.5%  
Book value per share (Unadj.) Rs255.1188.7 135.2%  
Shares outstanding (eoy) m88.022,399.26 3.7%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.02.9 170.1%   
Avg P/E ratio x26.422.9 115.2%  
P/CF ratio (eoy) x22.215.4 144.7%  
Price / Book Value ratio x4.52.1 214.6%  
Dividend payout %20.522.9 89.3%   
Avg Mkt Cap Rs m102,081958,864 10.6%   
No. of employees `0006.817.8 38.3%   
Total wages/salary Rs m4,30763,624 6.8%   
Avg. sales/employee Rs Th3,022.618,490.6 16.3%   
Avg. wages/employee Rs Th633.43,582.6 17.7%   
Avg. net profit/employee Rs Th569.12,357.6 24.1%   
INCOME DATA
Net Sales Rs m20,554328,375 6.3%  
Other income Rs m2116,360 3.3%   
Total revenues Rs m20,765334,735 6.2%   
Gross profit Rs m5,66469,898 8.1%  
Depreciation Rs m72120,528 3.5%   
Interest Rs m123,027 0.4%   
Profit before tax Rs m5,14352,702 9.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m1,2738,228 15.5%   
Profit after tax Rs m3,87041,868 9.2%  
Gross profit margin %27.621.3 129.5%  
Effective tax rate %24.815.6 158.6%   
Net profit margin %18.812.8 147.7%  
BALANCE SHEET DATA
Current assets Rs m11,812316,542 3.7%   
Current liabilities Rs m3,776157,064 2.4%   
Net working cap to sales %39.148.6 80.5%  
Current ratio x3.12.0 155.2%  
Inventory Days Days7788 88.4%  
Debtors Days Days82105 77.9%  
Net fixed assets Rs m14,398243,102 5.9%   
Share capital Rs m1752,399 7.3%   
"Free" reserves Rs m22,277450,245 4.9%   
Net worth Rs m22,452452,645 5.0%   
Long term debt Rs m720,289 0.0%   
Total assets Rs m26,962682,525 4.0%  
Interest coverage x444.318.4 2,413.7%   
Debt to equity ratio x00 0.7%  
Sales to assets ratio x0.80.5 158.4%   
Return on assets %14.46.6 218.9%  
Return on equity %17.29.2 186.3%  
Return on capital %23.011.2 204.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68274,219 14.4%   
Fx outflow Rs m2,10227,964 7.5%   
Net fx Rs m8,58046,255 18.5%   
CASH FLOW
From Operations Rs m3,74865,548 5.7%  
From Investments Rs m-2,228-25,888 8.6%  
From Financial Activity Rs m-1,475-57,151 2.6%  
Net Cashflow Rs m45-13,857 -0.3%  

Share Holding

Indian Promoters % 73.8 63.7 115.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.1 30.2%  
FIIs % 7.6 23.0 33.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.3 204.8%  
Shareholders   20,968 133,026 15.8%  
Pledged promoter(s) holding % 4.4 0.5 828.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA  SANOFI INDIA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 19, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS